Full Title
Epcoritamab with Lenalidomide and Tafasitamab in Patients with Relapsed/ Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) (ECLAT)Purpose
Researchers want to see how well epcoritamab with tafasitamab and lenalidomide works in people with lymphoma. The people in this study have diffuse large B cell lymphoma (DLBCL) that came back or keeps growing after treatment.
Epcoritamab is a type of drug called a bispecific antibody. It binds to one protein on the surface of cancer cells and another protein on immune cells called T cells. When epcoritamab attaches to these proteins at the same time, it activates T cells to kill cancer cells. It is given as a subcutaneous (under the skin) injection.
Tafasitamab blocks a protein in the body called CD19, which can cause tumors to grow. It helps the immune system target and destroy cancer cells. It is given intravenously (by vein).
Lenalidomide works against cancer cells by helping to change or control the functioning of the immune system. It is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have DLBCL that came back or keeps growing after treatment.
- Not be able to have CAR T cell therapy or autologous stem cell transplant, or your cancer got worse after one of these treatments.
- Have the CD20 and CD19 proteins on your cancer.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Pallawi Torka’s office at 201-775-7808.